AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Track explosive biotech opportunities with Biotech Fury – your real-time guide to small-cap pharmaceutical companies with breakthrough potential. Focus on FDA approvals, clinical trial catalysts, and regulatory milestones that drive stock price surges.
Comparative Report: MBRX, CCCC, COYA, CUE | Report Comparativo
? Comparative Report / Report Comparativo
MBRX | CCCC | COYA | CUE – Analisi Target, Finanziari e Catalyst
? Updated / Aggiornato: November 13, 2025
? Moleculin Biotech
NASDAQ: MBRX
$0.49
Market Cap: $23.7M
? Target Price
Bull: $4.00 – $8.00 (avg $5.00)
Upside: +1,142% ?
Bear: Sub-$0.30 (trial failure risk)
Rating: Strong Buy (2 Buy, 1 Sell)
? Financial Overview
Cash Q2 2025
$7.56M
Debt
$0.45M
Equity
-$7.2M ⚠️
Burn Rate
$5-6M/Q
Runway
Mid 2026
Net Loss 2024
-$21.76M
? Key Catalysts
MIRACLE Trial – Phase 3 AML
- Q4 2025: 45th patient enrollment + first unblinding
- H1 2026: Second unblinding
- Trial: Global (US, EU, Middle East) with Annamycin
- Status: 13 patients enrolled (Sept 2025)
- FDA: Fast Track + Orphan Drug designation
⚠️ HIGH RISK
Negative equity, high burn rate, everything depends on MIRACLE results. Strong dilution likely.
? C4 Therapeutics
NASDAQ: CCCC
$2.45
Market Cap: $228M
? Target Price
Bull: $10.00
Upside: +308% ?
Consensus: $8.50 (+247%)
Rating: Strong Buy/Hold (4 Buy, 2 Hold, 1 Sell)
? Financial Overview
Cash Q3 2025
$199.8M
Oct Raise 2025
+$125M ✅
Total Cash
$324.8M ✅
Runway
End 2028 ✅
Revenue Q3
$11.2M
Burn Rate
~$30M/Q
? Key Catalysts
TORPEDO Platform – Protein Degradation
- Cemsidomide: Phase 1/2 MM & NHL – 36% ORR (ASH data)
- Q1 2026: Phase 2 MOMENTUM combo trial
- CFT1946: BRAF V600X solid tumors – Data H2 2025
- $125M Raise: Oct 2025 – Funding through end 2028
- Biogen: Partnership milestone $8M already triggered
⚡ MOD-HIGH RISK
Clinical-stage biotech with excellent runway (2028). High burn but abundant cash. Phase 1/2 trials.
? Coya Therapeutics
NASDAQ: COYA
$6.09
Market Cap: $103M
? Target Price
Bull: $18.00 (HC Wainwright)
Upside: +179% ?
Consensus: $16.20-$17.00 (+163%)
Rating: Strong Buy ⭐ (7/7 analysts all Buy!)
? Financial Overview
Cash Q3 2025
$28.1M
Debt
$0 (debt-free) ✅
Equity
$28.3M
Burn Rate
$2.1M/Q ✅
Runway
H2 2027 ✅
Net Loss Q3
-$2.1M (-48% YoY) ↓
? Key Catalysts
COYA 302 – Phase 2 ALS Trial (ALSTARS)
- 2026: Phase 2 ALS data readout (KEY catalyst)
- FDA: IND acceptance received for COYA 302 ✅
- FTD Trial: Enrollment completed
- COYA 303: Promising preclinical data
- Partnership: $3.6M Q3 revenue from DRL collaboration
⚡ MOD-HIGH RISK
Excellent balance sheet (debt-free, runway 2027). Everything depends on ALS readout 2026. Unanimous analyst support.
? Cue Biopharma
NASDAQ: CUE
$0.70
Market Cap: $60M
? Target Price
Bull: $6.00-$8.00 (Stifel)
Upside: +757-1,043% ??
Consensus: $4.00 (+471%)
Rating: Strong Buy (4 analysts all Buy)
? Financial Overview
Cash Q3 2025
$11.7M ⚠️
Debt
$2.4-6.6M
Equity
$18.2M
Burn Rate
$8.5M/Q ⚠️
Runway
3-4 Q ⚠️⚠️
Revenue TTM
$8M (collab)
? Key Catalysts
CUE-401 & ImmunoScape Deal
- Q4 2025: $10M payment from ImmunoScape ?
- Nov 2026: $5M second payment
- Equity: 40% stake in ImmunoScape
- Milestones: Up to $345M potential
- CUE-101: HPV+ cancer – 50% ORR, 88% OS@12mo
? VERY HIGH RISK
Going concern notice! Runway <1 year. Critical dependency on Q4 2025 ImmunoScape payment. High dilution inevitable.
? Quick Comparison Table / Tabella Comparativa
| Company | Price | Market Cap | Target Upside | Cash Runway | Risk | Catalyst Timeline |
|---|---|---|---|---|---|---|
| MBRX | $0.49 | $24M | +1,142% | Mid 2026 | High | Q4 2025-H1 2026 |
| CCCC | $2.45 | $228M | +246-308% | End 2028 | Mod-High | 2025-2026 (Phase 2) |
| COYA | $6.09 | $103M | +163% | H2 2027 | Mod-High | 2026 (ALS readout) |
| CUE | $0.70 | $60M | +471% | 3-4 Q ⚠️ | Very High | Q4 2025 (funding) |
? Investment Summary / Sintesi Investitori
? BEST RISK/REWARD: COYA
- ✅ Unanimous analyst consensus (7/7 all Buy)
- ✅ Best balance sheet in biotech sector (debt-free, $28M cash)
- ✅ Runway to H2 2027
- ✅ Burn rate declining (-48% YoY)
- ✅ Upside +163% with contained downside
- RECOMMENDATION: BUY for 2-5 years, target ALS readout 2026
? SECOND CHOICE: CCCC (C4 Therapeutics)
- ✅ Runway to end 2028 (excellent)
- ✅ $125M raise just completed (Oct 2025)
- ✅ TORPEDO protein degradation platform
- ✅ Upside +246-308%
- RECOMMENDATION: BUY for 1-2 years, watch Phase 2 trials 2026
? HIGH RISK SPECULATION: MBRX
- ? Upside +1,142% if MIRACLE trial positive
- ? Q4 2025 catalyst imminent (critical data)
- ? High failure risk if trial negative
- RECOMMENDATION: Max 1% of portfolio for speculators only
? SURVIVAL BET: CUE
- ⚠️ Going concern – survival depends on Q4 2025 ImmunoScape payment
- ⚠️ Runway <1 year (critical)
- ⚠️ Upside +471-1,043% if saves
- RECOMMENDATION: Avoid unless extreme risk taker. Max 0.5% if any